A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer.

Background: Bone-targeted agents are usually administered to breast cancer patients with bone metastases every 3-4 weeks. Less frequent ('de-escalated') treatment may provide similar benefits with improved safety and reduced cost.

Methods: To systematically review randomised trials comparing de-escalated treatment with bone-targeted agents (i.